1. Home
  2. TECX vs GNE Comparison

TECX vs GNE Comparison

Compare TECX & GNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • GNE
  • Stock Information
  • Founded
  • TECX 2019
  • GNE 2011
  • Country
  • TECX United States
  • GNE United States
  • Employees
  • TECX N/A
  • GNE N/A
  • Industry
  • TECX
  • GNE Power Generation
  • Sector
  • TECX
  • GNE Utilities
  • Exchange
  • TECX Nasdaq
  • GNE Nasdaq
  • Market Cap
  • TECX 387.1M
  • GNE 407.6M
  • IPO Year
  • TECX 2018
  • GNE N/A
  • Fundamental
  • Price
  • TECX $19.02
  • GNE $15.80
  • Analyst Decision
  • TECX Buy
  • GNE
  • Analyst Count
  • TECX 6
  • GNE 0
  • Target Price
  • TECX $79.17
  • GNE N/A
  • AVG Volume (30 Days)
  • TECX 515.4K
  • GNE 142.6K
  • Earning Date
  • TECX 11-06-2025
  • GNE 11-03-2025
  • Dividend Yield
  • TECX N/A
  • GNE 1.94%
  • EPS Growth
  • TECX N/A
  • GNE 4.51
  • EPS
  • TECX N/A
  • GNE 0.31
  • Revenue
  • TECX N/A
  • GNE $456,876,000.00
  • Revenue This Year
  • TECX N/A
  • GNE $14.60
  • Revenue Next Year
  • TECX N/A
  • GNE $8.64
  • P/E Ratio
  • TECX N/A
  • GNE $38.50
  • Revenue Growth
  • TECX N/A
  • GNE 3.75
  • 52 Week Low
  • TECX $13.70
  • GNE $13.05
  • 52 Week High
  • TECX $61.07
  • GNE $28.47
  • Technical
  • Relative Strength Index (RSI)
  • TECX 61.68
  • GNE 51.74
  • Support Level
  • TECX $16.98
  • GNE $15.22
  • Resistance Level
  • TECX $18.77
  • GNE $16.28
  • Average True Range (ATR)
  • TECX 1.30
  • GNE 0.43
  • MACD
  • TECX 0.54
  • GNE 0.11
  • Stochastic Oscillator
  • TECX 96.12
  • GNE 66.77

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About GNE Genie Energy Ltd. Class B Stock

Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.

Share on Social Networks: